AUS-131
As of the edition of 20 October 2026, AUS-131 is a small molecule: in active development; acts on ESR2.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2009
- Kind
- Small molecule
- Registered trials
- 10, 0 stopped early
- Disease areas
- Mental health; Nervous system; Urinary and reproductive; Cancer; Pregnancy and women's health; Skin and connective tissue
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| ESR2 | Estrogen receptor beta | Q92731 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 1 | 0 | 0 |
| Phase 1 | 4 | 4 | 0 | 0 |
| Phase 2 | 5 | 3 | 2 | 0 |
| All trials | 10 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Ausio Pharmaceuticals | Lead sponsor of trials | 2008 to now |
| Pharmavite | Lead sponsor of trials | 2019 to now |